Choosing a Radioisotope and Calculating Storage Time
A hospital pharmacy receives a shipment of iodine-131 with an initial activity of 800 MBq. Iodine-131 has a half-life of 8.0 days and emits beta particles and gamma rays. The same pharmacy also has technetium-99m, which has a half-life of 6.0 hours and emits gamma rays. A physician needs one isotope to image a patient's thyroid gland and another isotope to destroy overactive thyroid tissue. The pharmacy must also store the unused iodine-131 until its activity falls below the release limit of 30 MBq. The radiation safety officer asks: how many days must the iodine-131 be stored before it can be released, and why does iodine concentrate in the thyroid gland in the first place? A student volunteer suggests using technetium-99m for the therapy because its shorter half-life means it will disappear faster. The officer asks for a correction based on the type of radiation and the chemical behavior of iodine.
1. Decide which isotope should be used for thyroid imaging and which for destroying overactive tissue. Justify using half-life and radiation type.
Read the worked answer
Technetium-99m for imaging. It emits gamma rays, which penetrate body tissue and can be detected outside the body by a gamma camera. Its 6.0-hour half-life is long enough to complete imaging but short enough that the patient's radiation dose does not persist unnecessarily.
Iodine-131 for therapy. It emits beta particles as well as gamma rays. Beta particles have a short range in tissue, so they deposit energy locally and damage overactive thyroid cells. Iodine-131 also has a longer half-life (8.0 days), which allows the radiation dose to act over time.
The key distinction is not simply 'short half-life is better.' Imaging needs penetrating radiation that can exit the body, while therapy needs locally damaging radiation and a chemical way to concentrate the isotope in the target tissue.
2. The iodine-131 shipment has an activity of 800 MBq. The release limit is 30 MBq. Using a half-life of 8.0 days, determine the minimum number of whole days before the sample can be released. Show the halving sequence.
Read the worked answer
Each half-life is 8.0 days. Halve the activity repeatedly:
- Start: 800 MBq
- 8.0 days: 400 MBq
- 16.0 days: 200 MBq
- 24.0 days: 100 MBq
- 32.0 days: 50 MBq
- 40.0 days: 25 MBq
At 32 days, the activity is 50 MBq, which is still above the 30 MBq release limit. At 40 days, the activity is 25 MBq, which is below 30 MBq.
Therefore, the minimum number of whole days before release is 40 days (5 half-lives).
3. A volunteer suggests using technetium-99m for therapy because its shorter half-life means it disappears faster. Correct this reasoning, and explain why iodine-131 concentrates in the thyroid gland even though the radiation comes from the nucleus.
Read the worked answer
A short half-life reduces the duration of radiation exposure, but it does not make an isotope a good therapy agent by itself. Technetium-99m emits gamma radiation, which is highly penetrating and tends to pass through tissue rather than deposit energy locally. That is useful for imaging, but it is not ideal for destroying a small region of overactive tissue.
Iodine-131 is effective for thyroid therapy because it emits beta particles, which have a short range and damage nearby cells. It also concentrates in the thyroid gland for a chemical reason: iodine is a Group 17 element and the thyroid uses iodine, just like stable iodine, to make thyroid hormones. The targeting comes from the element's chemical behavior, not from its radioactivity. The radiation itself comes from the nucleus, but the body's uptake and retention of iodine are chemical processes.